Patient-Reported Outcomes Measure Developed to Assess Quality of Life in Huntington’s Disease
Researchers have developed the Huntington’s Disease Manifest Quality of Life (HD-mQoL) measure to better track patient well-being. According to a paper in the Journal of Neurology, Isobel Spray of Galen Research and colleagues created this needs-based tool to capture lived experiences in a disease that currently lacks curative treatments.
Why was a new quality of life measure needed for Huntington’s disease?
Huntington’s disease is a hereditary neurodegenerative disorder. Because no curative treatments currently exist, quality of life (QoL) serves as a primary metric for assessing how therapies perform.
According to the researchers, existing HD-specific patient-reported outcomes measures failed to adequately capture the actual lived experience of those with the condition. The HD-mQoL was designed as the first needs-based, HD-specific tool to fill this gap.
How was the HD-mQoL developed and validated?
The development process involved three distinct stages. First, the team generated content through qualitative interviews and translated draft items into four languages.
Second, patients with HD participated in cognitive debriefing interviews. These sessions allowed researchers to refine the instructions and the items within the measure.
The final stage involved a validation survey completed by 238 participants. A second survey, administered two weeks later to 181 participants, assessed test-retest reliability.
What are the technical results of the HD-mQoL study?
Researchers used Rasch Measurement Theory and Classical Test Theory to analyze the data. This process reduced an initial list of 49 items down to a final set of 23.
The final measure demonstrated a model fit with an item–trait interaction χ2 of 0.391. It showed excellent reliability, with Cronbach’s α measuring 0.91 at the first timepoint and 0.92 at the second, and a test–retest r of 0.87.
The results indicated minimal floor and ceiling effects. The HD-mQoL also showed a moderate-to-strong correlation with relevant Nottingham Health Profile domains and effectively differentiated patient subgroups based on general health and self-rated disease severity.
What happens next for HD-mQoL implementation?
The authors state that the HD-mQoL is robust and suitable for international use. It may be integrated into both clinical practice and clinical trials to assess treatment value.
Future applications could involve using the 23-item set to monitor disease progression in real-time. This may help researchers determine if new interventions are improving the daily lived experience of patients.
Frequently Asked Questions
What is the HD-mQoL?
It is the first needs-based, Huntington’s disease-specific patient-reported outcomes measure used to assess the quality of life for patients.
How many items are in the final HD-mQoL measure?
The initial 49 items were reduced to a final set of 23 items after validation.
Which countries contributed to the development of the measure?
Content was generated through interviews in the United Kingdom, Ireland, the Czech Republic, Germany, Italy, and the Netherlands.
How do you think patient-reported outcomes change the way medical trials are conducted?